search
Back to results

Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache

Primary Purpose

Migraine Disorders

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Metamizol
Acetylsalicylic acid (ASA)
Metamizol placebo
ASA placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine Disorders

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female patients between 18 and 65 years old
  • Moderate episodic tension headache according to International Headache Society (I.H.S.) classification 2.1 (2.1.1 and 2.1.2) for at least one year
  • At least two episodes of tension headache per month in the last three months prior to enrolment into this trial
  • The episodes of tension headaches were usually treated by the patient successfully with a non-opioid-analgesic
  • First episodic headache occurred at an age under 50 years
  • Written informed consent according to Good Clinical Practice (GCP) and local regulations
  • The patient was able to fill in the Patient's Diary

Exclusion Criteria:

  • The patient usually needs for successful treatment of tension headache "Over The Counter" (OTC) analgesic in doses exceeding the doses tested here
  • The patient takes an OTC-analgesic normally at the first signs of an episode of tension headache
  • The patient has more than 15 episodes of tension headache per month
  • Female patients whose episodic tension headache is strongly correlated with the start of hormonal contraception
  • Concomitant treatment with (non-) prescriptional analgesics
  • Pre- (less than 4 weeks prior to inclusion in this trial) and/or concomitant treatment with an antidepressive and/or antipsychotic drug
  • Pre- (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug such as NSAIDs (Non-Steroidal Anti Inflammatory Drugs), propanolol, metroprolol, flunarizin, cyclandelate, valproic-acid, serotonergic antagonists, ergotamine, dihydroergotamines and benzodiazepines that may influence the headache symptomatology
  • Use of benzodiazepines in the previous 24 hours to the administration of the study drug. Occasional use of benzodiazepines - up to 3 per week - is allowed
  • Use of any drug with analgesic properties in the previous 24 hours to the administration of the study drug
  • Concomitant treatment with any drug containing ASA and/or metamizol
  • Concomitant treatment with anticoagulants such as heparin or coumarin-derivatives
  • Alcohol and drug abuse according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders )
  • Female patients in child-bearing age not using adequate means of birth control
  • Pregnancy and/or lactation
  • Gastrointestinal ulcers
  • Liver and/or renal disease
  • Bronchial asthma
  • Relevant allergy or known hypersensitivity to the investigational drugs, its excipients and/or to other NSAIDs
  • Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
  • Patients with active gastroesophageal flux disease (Amendment number 1)
  • Concomitant treatment with analgesics or any other drug that may have influenced the headache symptomatology - including metamizol or ASA -, was referred to its use during the headache episodes under evaluation. As long as appropriate wash-out periods were respected, analgesics were allowed in between the episodes of tension headache (TH) and their use as a rescue medication did not lead to the exclusion of the patient (Amendment number 2)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Active Comparator

    Placebo Comparator

    Arm Label

    Metamizol high & Placebo

    Metamizol low & Placebo

    Acetylsalicylic acid & Placebo

    Placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    Time-interval weighted sum of pain intensity difference (SPID) on a Visual Analogue Scale (VAS)

    Secondary Outcome Measures

    Pain intensity difference (PID) on a VAS
    Maximum pain intensity difference (MAXPID) on a VAS
    Number of patients with at least a 50% pain reduction on a VAS
    Time to 50% pain intensity reduction on a VAS
    Maximum pain relief (MAXPAR) on a Verbal Rating Scale (VRS)
    Total pain relief (TOTPAR) on a VRS
    Number of patients using rescue medication
    Global efficacy assessment on a VRS by the patient and investigator
    Number of patients with adverse events

    Full Information

    First Posted
    July 4, 2014
    Last Updated
    July 4, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02183220
    Brief Title
    Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache
    Official Title
    A Randomised, Double Blind, Placebo- and Active-controlled Parallel Group Study Investigating the Efficacy and Tolerability of Metamizol 0.5 g and 1.0 g in Patients With Episodic Moderate Tension Headache.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    October 1998 (undefined)
    Primary Completion Date
    July 1999 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    The objective of the study was to evaluate the efficacy, safety and tolerability of a single peroral dose of 0.5 g and 1.0 g metamizol relative to placebo and 1.0 g acetylsalicylic acid in 2 episodes of moderate tension headache.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Migraine Disorders

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    417 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Metamizol high & Placebo
    Arm Type
    Experimental
    Arm Title
    Metamizol low & Placebo
    Arm Type
    Experimental
    Arm Title
    Acetylsalicylic acid & Placebo
    Arm Type
    Active Comparator
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Metamizol
    Intervention Type
    Drug
    Intervention Name(s)
    Acetylsalicylic acid (ASA)
    Intervention Type
    Drug
    Intervention Name(s)
    Metamizol placebo
    Intervention Type
    Drug
    Intervention Name(s)
    ASA placebo
    Primary Outcome Measure Information:
    Title
    Time-interval weighted sum of pain intensity difference (SPID) on a Visual Analogue Scale (VAS)
    Time Frame
    before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
    Secondary Outcome Measure Information:
    Title
    Pain intensity difference (PID) on a VAS
    Time Frame
    before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
    Title
    Maximum pain intensity difference (MAXPID) on a VAS
    Time Frame
    before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
    Title
    Number of patients with at least a 50% pain reduction on a VAS
    Time Frame
    before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
    Title
    Time to 50% pain intensity reduction on a VAS
    Time Frame
    before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
    Title
    Maximum pain relief (MAXPAR) on a Verbal Rating Scale (VRS)
    Time Frame
    30 minutes, 1, 2, 3, and 4 hours after drug intake
    Title
    Total pain relief (TOTPAR) on a VRS
    Time Frame
    30 minutes, 1, 2, 3, and 4 hours after drug intake
    Title
    Number of patients using rescue medication
    Time Frame
    2, 3, and 4 hours after drug intake
    Title
    Global efficacy assessment on a VRS by the patient and investigator
    Time Frame
    4 hours after drug intake
    Title
    Number of patients with adverse events
    Time Frame
    up to 2 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male and female patients between 18 and 65 years old Moderate episodic tension headache according to International Headache Society (I.H.S.) classification 2.1 (2.1.1 and 2.1.2) for at least one year At least two episodes of tension headache per month in the last three months prior to enrolment into this trial The episodes of tension headaches were usually treated by the patient successfully with a non-opioid-analgesic First episodic headache occurred at an age under 50 years Written informed consent according to Good Clinical Practice (GCP) and local regulations The patient was able to fill in the Patient's Diary Exclusion Criteria: The patient usually needs for successful treatment of tension headache "Over The Counter" (OTC) analgesic in doses exceeding the doses tested here The patient takes an OTC-analgesic normally at the first signs of an episode of tension headache The patient has more than 15 episodes of tension headache per month Female patients whose episodic tension headache is strongly correlated with the start of hormonal contraception Concomitant treatment with (non-) prescriptional analgesics Pre- (less than 4 weeks prior to inclusion in this trial) and/or concomitant treatment with an antidepressive and/or antipsychotic drug Pre- (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug such as NSAIDs (Non-Steroidal Anti Inflammatory Drugs), propanolol, metroprolol, flunarizin, cyclandelate, valproic-acid, serotonergic antagonists, ergotamine, dihydroergotamines and benzodiazepines that may influence the headache symptomatology Use of benzodiazepines in the previous 24 hours to the administration of the study drug. Occasional use of benzodiazepines - up to 3 per week - is allowed Use of any drug with analgesic properties in the previous 24 hours to the administration of the study drug Concomitant treatment with any drug containing ASA and/or metamizol Concomitant treatment with anticoagulants such as heparin or coumarin-derivatives Alcohol and drug abuse according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders ) Female patients in child-bearing age not using adequate means of birth control Pregnancy and/or lactation Gastrointestinal ulcers Liver and/or renal disease Bronchial asthma Relevant allergy or known hypersensitivity to the investigational drugs, its excipients and/or to other NSAIDs Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial Patients with active gastroesophageal flux disease (Amendment number 1) Concomitant treatment with analgesics or any other drug that may have influenced the headache symptomatology - including metamizol or ASA -, was referred to its use during the headache episodes under evaluation. As long as appropriate wash-out periods were respected, analgesics were allowed in between the episodes of tension headache (TH) and their use as a rescue medication did not lead to the exclusion of the patient (Amendment number 2)

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1093/1093.16_U00-0018.pdf
    Description
    Related Info

    Learn more about this trial

    Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache

    We'll reach out to this number within 24 hrs